#oralsemaglutude #CKM #semaglutide #T2DM #GLP1s #CVOT #SoulClinicalTrial #Soul SOUL Trial: Oral Semaglutide Reduces Cardiovascular Events in T2DM Patients The SOUL Clinical Trial The SOUL trial was a landmark phase 3b, randomized, double blind, placebo controlled cardiovascular outcomes trial that evaluated oral semaglutide in 9,650 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, chronic kidney disease, or both
These medications work by binding to GLP-1 receptors in the body, which increases insulin production in response to food intake and suppresses glucagon, a hormone that raises blood sugar
All-inclusive pricing &bull
Research in female rats indicates that ipamorelin administration may boost bone mineral content, which results in improved bone density and reduced frailty [22]
This means patients only progress after demonstrating good tolerance and stable results on lower doses